Oncotelic Therapeutics Reports $249 Million Net Income for FY 2025 Driven by Joint Venture Valuation
Oncotelic Therapeutics announced a dramatic financial turnaround with $249 million net income for fiscal year 2025, primarily due to a non-cash gain from its GMP Biotechnology joint venture valuation, signaling potential growth in its oncology and COVID-19 drug pipeline.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported financial results for the fiscal year ended December 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in FY 2024. The dramatic turnaround was primarily driven by a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture, partially offset by a deferred tax provision of $111.6 million.
The company's financial performance reflects the growing value of its joint venture with Dragon, which is developing multiple compounds through GMP Bio. The joint venture is currently developing OT-101 along with five additional compounds for various cancers and COVID-19, and is developing five additional nanoparticle compounds that have the potential for significant revenues and value. This valuation gain indicates investor confidence in the company's pipeline and strategic partnerships.
Oncotelic's diverse portfolio includes multiple development programs beyond the joint venture. The company acquired apomorphine for Parkinson's Disease, erectile dysfunction and female sexual dysfunction, and is evaluating further development of OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes. Additionally, the company is developing CA4P in combination with a checkpoint inhibitor for advanced metastatic melanoma treatment.
The company's expansion into animal health through Pet2DAO represents another strategic growth area. Oncotelic's internet address is https://www.oncotelic.com where investors can find additional corporate information. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
This financial report comes through BioMedWire, a specialized communications platform focused on biotechnology and biomedical sciences developments. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that provides distribution services to financial markets. More information about BioMedWire is available at https://www.BioMedWire.com with full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.
The substantial non-cash gain from the joint venture valuation suggests that Oncotelic's strategic partnerships and diversified pipeline are creating significant enterprise value. While the gain is non-cash, it reflects market recognition of the company's assets and future revenue potential from its oncology, COVID-19, and other therapeutic programs. The financial results position Oncotelic with enhanced balance sheet strength as it continues clinical development across multiple therapeutic areas.